NCT01396577

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine that three 2-mg tablets of perampanel are bioequivalent to one 6-mg tablet of perampanel.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	perampanel	3 x 2 mg perampanel once per day
DRUG	perampanel	6 mg perampanel once per day

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-03-01
• Completion: 2011-04-01
• First posted: 2011-07-19
• Last updated: 2012-05-04

Locations

1 site across 1 country: United States